Clinical trials show 89% correlation with lab tests in metabolic cancer therapy, indicating advanced monitoring capabilities.
Background: Metabolic therapies (ketogenic diets, fasting) show promise in oncology but lack real-time monitoring tools.Innovation: We present an embedded system combining: MEMS-based ketone/glucose biosensors (0.1mM resolution) Edge-AI processing (STM32H743 MCU) Closed-loop feedback to mobile appsResults: Clinical trials (N=23) demonstrated: 89% correlation with lab tests (p<0.01) 12.3mW power consumption (72hr operation)Impact: Enables precision delivery of metabolic therapy.
No takes yet. Share an insight, caveat, or question.
Sudhakar Geruganti (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: